One hundred and twenty-one patients with HeV-related chronic hepatitis and normal baseline thyroid function were studied. Forty-six patients received IFN alpha-2b, while 75 patients had Peg-IFN alpha-2b with ribavirin more recently. Thirty patients (ten belonging to the standard IFN group) were re-treated. The pre-treatment prevalence of thyroid antibodies was 3.3%. At the end of the first antiviral treatment, the prevalence of laboratory alterations (presence of antibodies and abnormal hormonal levels) of thyroid was assessed to be 20.7% (25 patients), being quite similar for standardinterferon-and pegylated-interferon-treated patients (P = 0.63). TSH level alteration was seen in eleven
patients (9.1% of the overall population and 44% of the antibodies positive patients), of whom ten were females. The anti-microsomal, anti-thyroperoxidase and anti-thyroglobulin antibodies, in combined or isolated presence, were detected in all 25 patients. During the re-treatment we noticed worsening only of previous thyroid abnormalities. No patient changed the antiviral schedule after the emerging of thyroid alterations. All eleven patients remained thyroid dysfunctional at the end of the follow-up (ten with Hashimoto's thyroiditis and one with Graves' disease), meanwhile the near totality of patients with presence of antibodies remained positive. Interestingly, eight out the 14 patients who showed mood disorders after antiviral therapy, belonged to the afore-mentioned cohort.
Complications of Hepatitis C Virus (HCY) infection are prevented by antiviral treatment. Clinicians need to be aware of the common sideeffects of this therapy so that appropriate counselling and testing can be instituted before and during this treatment. Of these side-effects, depression in chronic HCY patients is significant, being related with illness perception, functional disability and impaired quality of life.
HCY-related chronic hepatitis (HCH) patients show various exaggerated immune manifestations (1), i.e., mixed cryoglobulinaemia and membrano-proliferative glomerulonephritis. Thyroid autoantibodies (Ab) are also common in HCY females, ranging from < 5 to > 15% (2). Antiviral treatment of HCH induces or worsens thyroid alterations (3) (4) . The aim of this study is to clarify the long-term behaviour of thyroid abnormalities after antiviral therapy.
MATERIALS AND METHODS
One hundred and twenty-one consecutive patients (mean age 54±12 years) of whom 64 were females (F), with HCH, high virological load (> 2,000,000 copies/mL or> 850,000 IU/mL), only genotype I, Ishak's fibrosis median score 2, range 1-3, and normal baseline thyroid function were studied. Forty-six patients, in the early 1990s, received standard IFN alpha-2b, 3 million units, thrice/week for 24-48 weeks, while seventy-five patients had more recently Pegylated (Peg)-IFN alpha-Zb, 1.5 meg/Kg/weekly, combined with ribavirin 800-1200 mg daily, based on body weight, for an equivalent period. The duration oftherapy was determined by the virological response, lasting up to 48 weeks in case of undetectable viral load at six-month-period. In the standard IFN group, 36 patients (78.3%) were non-responders or relapsers and ten of them (27.8%) were re-treated at the same schedule. In the opposite group, 37 patients (49.3%) were responders; of the 38 remaining, 20 patients (52.6%) were offered a new treatment at the similar dosage. The median (range) follow-up at our out-patient clinic was 59 (46-79) for the Peg-IFN alpha-2b, and 138 (111-168) months for the standard IFN alpha-2b group, respectively. Assays for anti-microsomal (anti-M), antithyroperoxidase (anti-TPO), anti-thyroglobulin antibodies (anti-T), serum thyroid-stimulating hormone (TSH) and free thyroxine and triiodothyronine levels were carried out before the start of therapy and every alternate month during the entire period oftreatment, and in the successive follow-up every three-or six-month intervals in patients with abnormal or normal thyroid profile, respectively. A dysphoric mood or depression presence was assessed according to DSM IV criteria, and its entity was assessed by the Beck Depression Inventory (BDI) scale, recently validated in this particular population (5) .
RESULTS
The pre-treatment prevalence of laboratory abnormalities (only thyroid auto-Ab) was 3.3% (four F patients, two in the standard IFN therapy group). After the first antiviral course, thyroid laboratory alterations amounted to 20.7%, 25 patients (21 F), being quite similar for standard-IFN-and Peg-IFNtreated patients (10/46, 21.7%, versus 15/75, 20%, chi square = 0.24, P = 0.63). The anti-M, anti-TPO and anti-T, at various titre, combined or isolated presence was detected in all the 25 patients. Thyroid dysfunction (TSH < 0.1 or > 5 mUlL) developed in eleven patients (9.1% of total patients, but 44% of thyroid auto-Ab positive). Female gender was significantly associated with thyroid dysfunction (ten out of eleven patients, chi square = 5.4, P = 0.02). Eight out ofeleven (72.7%) patients remained thyroid dysfunctional (all with Hashimoto's thyroiditis, often preceded by a transient thyrotoxicosis); one patient (9.1%) with Graves' disease was treated by anti-thyroidal agents for 18 months, meanwhile the other two (18.2%) presented a transient subclinical hypothyroidism. The near totality (22 out of 25) of patients remained positive for auto-Abo Particularly, the four patients with pre-treatment auto-Ab showed a Hashimoto's thyroiditis. The onset of thyroid laboratory abnormalities was at a median time of four months (range three-six months). Regarding the 30 re-treated patients (18 F), 26 (86.7%; 15 F) never showed thyroid abnormalities (serology and function) even after the second antiviral course; two out of the remaining patients (three F), with transient subclinical hypothyroidism at the first treatment, ended with Hashimoto's thyroiditis, necessitating long-term levothyroxine replacement; one male patient, already presenting a Hashimoto's thyroiditis, needed a substitutive therapy dosage increase; the last one was characterized by an early Graves' disease relapse. For the 25 patients showing thyroid auto-Ab during antiviral therapy, no risk factor except the gender, OR = 4.5 (i .6-13.1), among age, TSH levels or antiviral therapy type predicted the thyroid alterations. On the other hand, the pretreatment thyroid auto-Ab positivity always ended up in clinical hypothyroidism. Interestingly, eight (57.1%) of the 14 patients who showed mood disorders after antiviral therapy (normal basal BDI score) belonged to the afore-mentioned cohort. Three of these patients showed a stability of the BDI scale, and five showed an improvement of >25%, only optimizing substitutive therapy. In the remaining six depressed patients, these disorders waxed and waned for the follow-up.
DISCUSSION
We did not follow a control population, assuming that the selected patients acted as auto-controls. Having studied only genotype 1 HCH patients does not represent a drawback, because this choice goes toward a certain homogeneity of therapy doses. This point is important because the immune-effect of IFN could be dose-dependent (6) . There seems to be a genetic predisposition unravelled by HCV infection and/or IFN alpha therapy, that predominantly affects females with haplotype HLA DR-3 (7) . Furthermore, IFN alpha would directly act on iodine metabolism (8) . Molecular mimicry, as proposed to explain the emergence of different auto-Ab (9) , could be an alternative pathogenetic mechanism. Long-term thyroid dysfunction and auto-Ab presence persisted in the major part of our patients, in all of them the antiviral schedule was carried out unmodified for at least three months, according to virological response, after the apperance of thyroid alterations. In our series the total dose and the type of IFN were not associated to the presence or increase of thyroid disorders, hypothesizing a cytokine-mediated Thl switching (10), but the prolonged treatment after thyroid derangement could explain the long persistence of alterations.
The finding of depression in HCH patients on antiviral therapy is frequent (11) , but the association of depression and abnormal thyroid function is a novel finding. Although IFN treatment can decrease the tryptophan availability for serotonin synthesis and the 5-hydroxyindoleacetic acid level in the locus control region, such as a modification of the central serotoninergic receptor (12) , it is likely that thyroid functional alterations contribute to the production or aggravation of mood disorders. The finding that depression often co-existswith autoimmune subclinical thyroiditis suggests that depression may cause alterations in the immune system, or that it could in fact be an autoimmune disorder itself. On the other hand, the outcome of antiviral treatment and the course of depression may also be related to thyroid status.
